|
|
|
|
Ambrilia Biopharma Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new market report released
Refer to a friend 2010-03-11 08:05:13 - Ambrilia Biopharma Inc.- Pharmaceuticals & Healthcare - Deals and Alliances Profile - a new market research report on companiesandmarkets.com Ambrilia Biopharma Inc. - Pharmaceuticals & Healthcare - Deals and...
|
|
|
Ambrilia Biopharma Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new market
www.companiesandmarkets.com/Summary-Company-Profile/ambrilia-bio ..Ambrilia Biopharma Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile is an essential source for company data and information. The profile examines the companys key...
|
|
|
Q Chip Ltd announces appointment of Tony Mills
Cardiff, UK, March 4th, 2010Q Chip Ltd, the biopharmaceutical company developing sustained release biotherapies, is pleased to announce that it has appointed Dr Tony Mills to its Board of Directors.Tony brings a wealth of experience in commercialising...
|
|
|
Gastrinoma Therapy: Researchers from Princess Margaret Hospital report on findings in gastrinoma therapy
Today's Medical & Research News Gastrinoma Therapy Researchers from Princess Margaret Hospital report on findings in gastrinoma therapy March 5th, 2010 Printer-Friendly Version Country:Hong Kong Gastrinoma Therapy Abdominal Pain Blood Pressure Drugs...
|
|
|
90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide [Gastrointestinal Cancer]
David L.Bushnell Jr,* Thomas M. O'Dorisio, M. Sue O'Dorisio, Yusuf Menda, Rodney J. Hicks, Eric Van Cutsem, Jean-Louis Baulieu, Francoise Borson-Chazot, Lowell Anthony, Al B. Benson, Kjell Oberg, Ashley B. Grossman, Mary Connolly, Hakim Bouterfa,...
|
|
|
SurModics Provides a Notice of Termination of a Product Licence Agreement
Ambrilia Biopharma Inc.(TSX: AMB) announced today that SurModics Pharmaceuticals, Inc., as a successor to Southern Research Institute (formerly Brookwood Pharmaceuticals, Inc. and now a wholly-owned subsidiary of SurModics, Inc.) provided Ambrilia with a...
|
|
|
Ambrilia Biopharma face product licence legal wrangle
Richard La Rue reports SURMODICS PROVIDES A NOTICE OF TERMINATION OF A PRODUCT LICENCE AGREEMENT SurModics Pharmaceuticals Inc., as a successor to Southern Research Institute (formerly Brookwood Pharmaceuticals, Inc.and now a wholly owned subsidiary of...
|
|
|
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round
Fundraising Follows Successful Clinical Proof-of-Concept With Glide's Solid Dose Injector Funding to Progress Glide Octreotide Into Clinical Development OXFORD, England, February 10 /PRNewswire/ -- Glide Pharma, a specialty pharmaceutical company focused...
|
|
|
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round Fundraising Follows Successful Clinical Proof-of-Concept With Glide's Solid Dose Injector Funding to Progress Glide Octreotide Into Clinical Development OXFORD, England,...
|
|
|
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round
Fundraising Follows Successful Clinical Proof-of-Concept With Glide's Solid Dose Injector Funding to Progress Glide Octreotide Into Clinical Development PR Newswire OXFORD, England, February 10 OXFORD, England, February 10 /PRNewswire/ -- Glide Pharma, a...
|
|
|
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round
Fundraising Follows Successful Clinical Proof-of-Concept With Glide's Solid Dose Injector Funding to Progress Glide Octreotide Into Clinical Development PR Newswire OXFORD, England, February 10 OXFORD, England, February 10 /PRNewswire/ -- Glide Pharma, a...
|
|
|
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round
Fundraising Follows Successful Clinical Proof-of-Concept With Glide's Solid Dose Injector Funding to Progress Glide Octreotide Into Clinical Development PR Newswire OXFORD, England, February 10 OXFORD, England, February 10 /PRNewswire/ -- Glide Pharma, a...
|
|
|
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round
Fundraising Follows Successful Clinical Proof-of-Concept With Glide's Solid Dose Injector Funding to Progress Glide Octreotide Into Clinical Development PR Newswire OXFORD, England, February 10 /PRNewswire/ -- Glide Pharma, a specialty pharmaceutical...
|
|
|
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round
Fundraising Follows Successful Clinical Proof-of-Concept With Glide's Solid Dose Injector Funding to Progress Glide Octreotide Into Clinical Development PR Newswire OXFORD, England, February 10 /PRNewswire/ -- Glide Pharma, a specialty pharmaceutical...
|
|
|
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round Fundraising Follows Successful Clinical Proof-of-Concept With Glide's Solid Dose Injector Funding to Progress Glide Octreotide Into Clinical Development OXFORD, England,...
|
|
|
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round
Fundraising Follows Successful Clinical Proof-of-Concept With Glide's Solid Dose Injector Funding to Progress Glide Octreotide Into Clinical Development PR Newswire OXFORD, England, February 10 /PRNewswire/ -- Glide Pharma, a specialty pharmaceutical...
|
|
|
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round
Fundraising Follows Successful Clinical Proof-of-Concept With Glide's Solid Dose Injector Funding to Progress Glide Octreotide Into Clinical Development PR Newswire OXFORD, England, February 10 /PRNewswire/ -- Glide Pharma, a specialty pharmaceutical...
|
|
|
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round
Fundraising Follows Successful Clinical Proof-of-Concept With Glide's Solid Dose Injector Funding to Progress Glide Octreotide Into Clinical Development PR Newswire OXFORD, England, February 10 /PRNewswire/ -- Glide Pharma, a specialty pharmaceutical...
|
|
|
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round
Fundraising Follows Successful Clinical Proof-of-Concept With Glide's Solid Dose Injector Funding to Progress Glide Octreotide Into Clinical Development PR Newswire OXFORD, England, February 10 OXFORD, England, February 10 /PRNewswire/ -- Glide Pharma, a...
|
|
|
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round
Fundraising Follows Successful Clinical Proof-of-Concept With Glide's Solid Dose Injector Funding to Progress Glide Octreotide Into Clinical Development PR Newswire OXFORD, England, February 10 /PRNewswire/ -- Glide Pharma, a specialty pharmaceutical...
|
|
|
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round
Fundraising Follows Successful Clinical Proof-of-Concept With Glide's Solid Dose Injector Funding to Progress Glide Octreotide Into Clinical Development PR Newswire OXFORD, England, February 10 /PRNewswire/ -- Glide Pharma, a specialty pharmaceutical...
|
|
|
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round
Fundraising Follows Successful Clinical Proof-of-Concept With Glide's Solid Dose Injector Funding to Progress Glide Octreotide Into Clinical Development PR Newswire OXFORD, England, February 10 /PRNewswire/ -- Glide Pharma, a specialty pharmaceutical...
|
|
|
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round
Fundraising Follows Successful Clinical Proof-of-Concept With Glide's Solid Dose Injector Funding to Progress Glide Octreotide Into Clinical Development PR Newswire OXFORD, England, February 10 /PRNewswire/ -- Glide Pharma, a specialty pharmaceutical...
|
|
|
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round
Fundraising Follows Successful Clinical Proof-of-Concept With Glide's Solid Dose Injector Funding to Progress Glide Octreotide Into Clinical Development PR Newswire OXFORD, England, February 10 /PRNewswire/ -- Glide Pharma, a specialty pharmaceutical...
|
|
|
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round
Fundraising Follows Successful Clinical Proof-of-Concept With Glide's Solid Dose Injector Funding to Progress Glide Octreotide Into Clinical Development PR Newswire OXFORD, England, February 10 OXFORD, England, February 10 /PRNewswire/ -- Glide Pharma, a...
|
